Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease in the United States. The company's product candidates comprise SYMJEPI epinephrine pre-filled syringe injectable products for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products for the treatment of asthma; and naloxone injection for the treatment of opioid overdose. It also offers APC400, a tempol gel use of reducing radiation dermatitis in patients undergoing treatment for cancer; and APC410 for the treatment of respiratory diseases, including asthma, respiratory syncytial virus, influenza, and COVID-19. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, and injectables; and veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation was founded in 2006 and is headquartered in San Diego, California.. The 2025 version of the report offers detailed insights into the company's strategies, developments, outlook and drivers. In addition to SWOT Analysis and Financial Overview, the report analyzes key projects, business description, products, services, brands, operating locations, subsidiaries and affiliates of Adamis Pharmaceuticals Corporation. Adamis Pharmaceuticals Corporation business operations across the value chain are included. Further, all major operating and planned locations, related contacts, details of subsidiaries and partnerships of Adamis Pharmaceuticals Corporation are also analyzed. Detailed SWOT Analysis of the company including key strengths and weaknesses of Adamis Pharmaceuticals Corporation , on which it can build its business along with potential opportunities and threats in the near to medium term future are detailed. Key employees of the company including the management team and board of directors are listed with their designations. Further, statistics on key parameters such as employee count, organization structure etc is provided. Financial analysis of Adamis Pharmaceuticals Corporation including key ratios, income statement, cash flow statement and balance sheet are provided for the company. In addition, Key historical events, summary analysis of Adamis Pharmaceuticals Corporation and all latest updates of the company are provided. The 2025 version of Adamis Pharmaceuticals Corporation report is presented after intensive primary and secondary research processes and it presents the insights in a complete impartial and reader friendly format.
